Gilead Sciences Inc $70.00

up +0.72


17/4/2014 08:10 PM  |  NASDAQ : GILD  
Industries : Drugs / Biotechnology
Get Trend Analysis Icon Get GILD Trend Analysis - it has outperformed the S&P 500 by 15%

Partner Headlines

  1. ObamaCare Hits UnitedHealth

    IBD
  2. UnitedHealth Earnings Drop on ObamaCare, Medicare Cuts

    IBD
  3. Has A Streamlined FDA Raised The Value Of Drug Stocks?

    IBD
  4. China's Weibo Set to Debut After Cutting IPO Size

    FoxBusiness
  5. J&J Earnings Beat Estimates As Pharma Sales Shine

    IBD
  6. Stocks: Thin Gains; Yellen Coaxes Banks To Fortify

    IBD
  7. Markets Falling? Get Your Defense Ready

    Benzinga
  8. Stocks Jump In Weak Trade

    IBD
  9. US Stock Futures Slip Ahead Of Consumer Sentiment Report

    Benzinga
  10. Merck Hep-C Combo Scores

    IBD
  11. Merck Hep-C Combo Scores

    IBD
  12. HCV Rivalry Heats Up As Merck Combo Shines In Trial

    IBD
  13. Stocks Fall In Higher Volume; Alexion, Gilead Drop 7%

    IBD
  14. Nasdaq Leads Broad Rout In Stock Market

    IBD
  15. Merck Hepatitis C Combo Scores 98% Cure Rate

    IBD
  16. Five Star Stock Watch: Gilead Sciences

    Benzinga
  17. Don't Panic Over Recent Tech Turmoil

    FoxBusiness
  18. Biotechs Struggling To Find A Bottom

    Benzinga
  19. Morning Market Losers

    Benzinga
  20. Benzinga's Top #PreMarket Losers

    Benzinga
  21. UPDATE: TD Ameritrade Says IMX for Mar. Up to 5.87

    Benzinga
  22. GILEAD SCIENCES

    IBD
  23. Gilead's HepC Drug Sales May Be More Resilient Than Feared

    Benzinga
  24. Meet the Nasdaq Composite 2.0

    FoxBusiness
  25. Nasdaq Leads Another Up Day; S&P 500 Hits All-Time High

    IBD
  26. Despite S&P 500's New High, Stocks Face Challenges

    Benzinga
  27. Gilead Adds To Biotech Woes

    IBD
  28. Gilead Sovaldi Scrips Falter As Biotechs Keep Falling

    IBD
  29. Rebound Rally Losing More Steam; BitAuto Hangs Tough

    IBD
  30. GILEAD SCIENCES'

    IBD
  31. Market Wrap For March 27: Markets Lower Following Mixed Economic Data

    Benzinga
  32. Morgan Stanley's Top Biotech Pick is Biogen

    Benzinga
  33. Top Industry Groups Take Big Hits In Market Sell-Off

    IBD
  34. Stocks Push Off Lows; Nu Skin Rallies

    IBD
  35. Have We Seen The Top Of The Market?

    Benzinga
  36. Weekly Insider Sells Highlight: KERX, ORCL, QCOM, GILD

    GuruFocus
  37. Weekly CFO Sells Highlight: Google Inc., Facebook Inc., Gilead Sciences ...

    GuruFocus
  38. Dems Question Gilead Price

    IBD
  39. Biotechs, Medicals Get Hurt Amid Price-Inquiry News

    IBD
  40. Biotechs, Software, Generics Pace U.S. Stocks Lower

    IBD
  41. House Probe Of Gilead's Sovaldi Price Hits Biotechs

    IBD
  42. Cambrex Keeps Its Pipeline Of New Products Flowing

    IBD
  43. Market Wrap For March 21: Markets End Friday On A Negative Note, But Still ...

    Benzinga
  44. U.S. Stocks Lose Gains, Biotechs Get Hammered

    IBD
  45. Gilead Pricing Probed By House; Biotech Stocks Drop

    IBD
  46. Nasdaq Back Above Water; Green Plains Jumps

    IBD
  47. Dow, S&P 500 Up, Nasdaq Slips; Drugmakers Falling Hard

    IBD
  48. Pharmacyclics target raised

    IBD
  49. Pharmacyclics Drug Imbruvica Beats Rivals: Nomura

    IBD
  50. Gilead's HCV Challengers Near The Starting Gate

    IBD
Trading Center